What does this research mean for the field?

Question

Accepted Answer

GLP-1 receptor agonists are effective for body weight reduction and glycaemic improvement as adjunctive therapy to insulin in individuals with type 1 diabetes and overweight or obesity, despite an increase in hypoglycaemic and gastrointestinal adverse events. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis

Discussion

Member takes

Overview

Key Points

Cite This Study